BIOMAT Database Logo BIOMAT Database Logo

Evaluation of the bioequivalence and pharmacokinetics of two lisinopril tablet formulations after single oral administration in healthy volunteers. 2004

Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Laboratory of Pharmaceutics and Drug Control, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece. mgeorgara@hotmail.com

An open, two-period, randomized, crossover trial of two lisinopril (1-[N2-[(S)-1-carboxyl-3-phenylpropyl]-L-lysil]-L-proline, CAS 76547-98-3) formulations (Adicanil as test and another commercially available preparation as reference) was performed in 24 healthy volunteers. A single 20 mg oral dose of lisinopril was administrated and pharmacokinetic parameters were compared. Lisinopril plasma concentrations were measured by a fully validated LC-MS method. The parametric 90% confidence intervals of the geometric mean values of the test/reference ratios were 95.38% to 105.94% (point estimate: 100.52%) for AUC(0-last), 94.01% to 103.47% (point estimate: 98.63%) for AUC(0-infinity) and 92.34% to 103.97% (point estimate: 97.98%) for Cmax, being within the acceptance criteria for bioequivalence (80%-125%). T(1/2), k(el) and Tmax values were also tested and the difference was not statistically significant. Therefore, it is concluded that the test and the reference lisinopril formulations are bioequivalent both in the extent and the rate of absorption.

UI MeSH Term Description Entries
D008297 Male Males
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D013058 Mass Spectrometry An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. Mass Spectroscopy,Spectrometry, Mass,Spectroscopy, Mass,Spectrum Analysis, Mass,Analysis, Mass Spectrum,Mass Spectrum Analysis,Analyses, Mass Spectrum,Mass Spectrum Analyses,Spectrum Analyses, Mass
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies

Related Publications

Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Bioequivalence of two tablet formulations of atenolol after single oral administration in healthy volunteers.
March 2000, Arzneimittel-Forschung,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
January 2002, Arzneimittel-Forschung,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Evaluation of the bioequivalence of two tablet formulations of enalapril/hydrochlorothiazide after single oral administration to healthy volunteers.
January 2004, Arzneimittel-Forschung,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Evaluation of the bioequivalence and pharmacokinetics of two formulations of secnidazole after single oral administration in healthy volunteers.
January 2007, Arzneimittel-Forschung,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Evaluation of the bioequivalence and pharmacokinetics of two formulations of rizatriptan after single oral administration in healthy volunteers.
January 2005, Arzneimittel-Forschung,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Bioequivalence evaluation of two sertraline tablet formulations in healthy male volunteers after a single dose administration.
March 1999, International journal of clinical pharmacology and therapeutics,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Bioequivalence of two rimantadine tablet formulations in healthy male volunteers after single dose administration.
April 2001, International journal of clinical pharmacology and therapeutics,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Pharmacokinetics of naproxen after oral administration of two tablet formulations in healthy volunteers.
June 1983, International journal of clinical pharmacology, therapy, and toxicology,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Bioequivalence of two fexofenadine formulations in healthy human volunteers after single oral administration.
June 2007, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia,
Manolis Georgarakis, and Andreas Tsakalof, and Fotini Zougrou, and Georgios Kontopoulos, and Iakovos Tsiptsios
Pharmacokinetic profiling and bioequivalence evaluation of 2 lamivudine tablet formulations after single oral administration in healthy human Indian volunteers.
April 2005, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!